文献速递哮喘慢阻肺

哮喘与慢阻肺中小气道疾病的七大支柱:支持新疗法开发的机遇

Seven Pillars of Small Airways Disease in Asthma and COPD: Supporting Opportunities for Novel Therapies.
PubMed 文献 · Chest · 2021-04-02

本文为专家意见,讨论哮喘和慢阻肺中小气道疾病,指出显著小气道功能障碍可在常规肺功能检出明显气道阻塞之前出现,而FEV1等常规指标与早期病理改变、症状及急性加重频率不完全一致。文章提出需开发小气道特异性终点以推动新疗法研发。

要点

  • 早期轻度阻塞性肺病已存在显著小气道功能障碍,可早于常规肺功能异常。
  • FEV1与早期病理改变、症状及急性加重频率可能不一致。
  • 需开发小气道特异性终点以推动新疗法研发和标准化。

核心结论

  • 改善对小气道功能障碍在早期气道疾病中作用的认识,并识别测量亚临床变化的新终点,可能促进直接针对早期气道疾病过程的新疗法开发,以延缓疾病进展和逆转损伤。

研究设计与样本

  • 专家意见论文,讨论哮喘和慢阻肺中小气道疾病,并指出阻碍早期识别阻塞性肺病及开发与标准化小气道特异性终点的知识空白。

主要发现

  • 显著小气道功能障碍可在常规肺功能技术检测到任何明显气道阻塞之前被发现。
  • 大多数阻塞性肺病治疗针对慢性肺病导致的生理改变和相关症状,而非直接针对气流中断的特定原因或疾病进展驱动因素。
  • 最广泛使用的FEV1与早期或轻度疾病的病理改变不一致,且可能与个体患者的症状或急性加重频率不一致。
  • 更新的功能和影像技术可更有效评估小气道功能障碍,但认识仍存在显著空白。

临床怎么用

  • 临床应关注小气道功能障碍在早期哮喘和慢阻肺中的作用,不应仅依赖FEV1评估早期或轻度疾病。
  • 可考虑使用更新的功能和影像技术评估小气道功能障碍。

局限性

  • 本文为专家意见论文,非系统综述或原始研究。
  • 对小气道功能障碍的认识仍存在显著空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identification of pathologic changes in early and mild obstructive lung disease has shown the importance of the small airways and their contribution to symptoms. Indeed, significant small airways dysfunction has been found prior to any overt airway obstruction being detectable by conventional spirometry techniques. However, most therapies for the treatment of obstructive lung disease target the physiological changes and associated symptoms that result from chronic lung disease, rather than directly targeting the specific underlying causes of airflow disruption or the drivers of disease progression. In addition, although spirometry is the current standard for diagnosis and monitoring of response to therapy, the most widely used measure, FEV1 , does not align with the pathologic changes in early or mild disease and may not align with symptoms or exacerbation frequency in the individual patient. Newer functional and imaging techniques allow more effective assessment of small airways dysfunction; however, significant gaps in our understanding remain. Improving our knowledge of the role of small airways dysfunction in early disease in the airways, along with the identification of novel end points to measure subclinical changes in this region (ie, those not captured as symptoms or identified through standard FEV1), may lead to the development of novel therapies that directly combat early airways disease processes with a view to slowing disease progression and reversing damage. This expert opinion paper discusses small airways disease in the context of asthma and COPD and highlights gaps in current knowledge that impede earlier identification of obstructive lung disease and the development and standardization of novel small airways-specific end points for use in clinical trials.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Usmani OS, Han MK, Kaminsky DA, et al. Seven Pillars of Small Airways Disease in Asthma and COPD: Supporting Opportunities for Novel Therapies. Chest. 2021. PMID: 33819471. doi:10.1016/j.chest.2021.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。